SRR13311174
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.590
- ANGIOGENESIS+0.530
- ALLOGRAFT_REJECTION+0.500
- INFLAMMATORY_RESPONSE+0.500
- IL2_STAT5_SIGNALING+0.480
- IL6_JAK_STAT3_SIGNALING+0.430
- KRAS_SIGNALING_UP+0.430
- WNT_BETA_CATENIN_SIGNALING+0.420
- HEDGEHOG_SIGNALING+0.400
- UV_RESPONSE_DN+0.380
Top 10 suppressed
- PANCREAS_BETA_CELLS-0.400
- SPERMATOGENESIS-0.200
- KRAS_SIGNALING_DN-0.160
- E2F_TARGETS-0.110
- G2M_CHECKPOINT-0.110
- INTERFERON_ALPHA_RESPONSE-0.110
- ESTROGEN_RESPONSE_LATE+0.020
- DNA_REPAIR+0.040
- P53_PATHWAY+0.060
- PEROXISOME+0.070
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
8 twins match this tumor's tissue · 2 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MBCProject_0022_T1_RNA | — | D | 0.872 |
| 2 | R242 | — | — | 0.865 |
| 3 | BS_2YCJV2VV | low-grade glioma | — | 0.863 |
| 4 | BS_4Z2F4P9N | pilocytic astrocytoma | — | 0.855 |
| 5 | R103 | — | — | 0.853 |
| 6 | TCGA-FD-A5BU-01A-31R-A26T-07 | — | — | 0.852 |
| 7 | 44B1F003-553A-4C8A-A6AE-44C49262081C | — | — | 0.849 |
| 8 | TCGA-56-5897-01A-11R-1635-07 | — | cohortSQ1 | 0.849 |
| 9 | 2D0A1BA3-EC1D-4B4F-A383-9353C0F4BE85 | — | — | 0.844 |
| 10 | 18D7DFBC-A1C6-4DA8-9AF1-3A6F3E2A03BE | — | — | 0.844 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 44 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.590 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.530 | Remibrutinib | — uncovered |
| ALLOGRAFT_REJECTION | 0.500 | Idelalisib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.500 | Idelalisib | — uncovered |
| IL2_STAT5_SIGNALING | 0.480 | Idelalisib | — uncovered |
| IL6_JAK_STAT3_SIGNALING | 0.430 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.430 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.420 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.400 | Inavolisib | — uncovered |
| UV_RESPONSE_DN | 0.380 | Inavolisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.360 | Inavolisib | — uncovered |
| NOTCH_SIGNALING | 0.330 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.330 | Idelalisib | — uncovered |
| APICAL_JUNCTION | 0.320 | Inavolisib | — uncovered |
| COMPLEMENT | 0.300 | Inavolisib | — uncovered |
| MYC_TARGETS_V1 | 0.300 | Inavolisib | — uncovered |
| TGF_BETA_SIGNALING | 0.290 | Inavolisib | — uncovered |
| INTERFERON_GAMMA_RESPONSE | 0.280 | Idelalisib | — uncovered |
| MTORC1_SIGNALING | 0.270 | Inavolisib | — uncovered |
| PROTEIN_SECRETION | 0.260 | Remibrutinib | — uncovered |